141
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Can the neutrophil–lymphocyte ratio predict type 1 hereditary angioedema attacks?

ORCID Icon & ORCID Icon
Pages 649-653 | Received 16 Apr 2020, Accepted 19 Sep 2020, Published online: 28 Sep 2020
 

Abstract

The neutrophil–lymphocyte ratio is a simple and easily used parameter for the assessment of inflammation. We aimed to determine the predictive potential of the neutrophil–lymphocyte ratio regarding episode occurrence in patients with hereditary angioedema. Sixty-six patients with Type 1 hereditary angioedema and 60 healthy controls were included in the study. The laboratory results of the patients in their episode-free periods were similar to those of the healthy controls. The median of neutrophil-lymphocyte ratio was higher during episodes when compared to normal periods (3.5 versus 2.0, p < .001). A significant positive correlation was present between the episode count and the neutrophil-lymphocyte ratio calculated during the episodes (r = 0.557, p < .001). We can conclude that the neutrophil-lymphocyte ratio, which is cheap and easy to calculate, can be used by clinicians as a predictive parameter for prediction of the episode count in patients with hereditary angioedema.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Disclosure statement

No potential conflict of interest was reported by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.